APG-20-OLE Metreleptin

Purpose: This study is being done to see whether a medication called metreleptin, also known as the study medication/treatment, is safe and works in patients with familial partial lipodystrophy (FPLD).

What Is Involved: If you decide you would like to participate in the study, you can expect to be in the study for a minimum of 24 months. There are 6 in-person visits and 1 phone call

Invasive Activities

Blood sample collection

Non-invasive Activities

Physical examination, Urine collection

Inclusion Criteria: At least 18 years of age, Diagnosis of FPLD, Took part in Parent study APG-20 and more....

Exclusion Criteria: Previous treatment with Metreleptin, Leptin greater than 20, APL, and more....

Principal Investigator:

Bradley Javorsky, MD
Dept. of Medicine
Division of Endocrinology and Molecular Medicine
262-253-7155
Bjavorsky@mcw.edu